Current U.S. HIV Market � $3.3Bn

U.S. Revenues per Treatment Class

Source: IMS Health � National Prescription Audit Data for 12 Months Ended 6/30/02

($Bn)

(7)

(3)

(6)

$1.9Bn

$0.4Bn

$1.0Bn

Combivir$0.6Bn

Viracept$0.4Bn

Sustiva$0.3Bn

Previous slide

Next slide

Back to first slide

View graphic version